Skip to:

Text size [+][-]  Thursday March 18 2010GLOBAL EDITION

Considered view
16 Nov 2009 20:57

Medicine for Apollo?

About Us

Breakingviews.com is the world's leading source of agenda-setting financial insight. breakingviews has 25 correspondents and columnists based in London, New York, Paris, Washington, San Francisco and Madrid. Our aim is to become the lingua franca for the global financial community. Our real-time subscription service currently reaches around 15,000 financial professionals such as investment bankers, senior corporate executives, hedge fund managers, lawyers and private equity professionals.

We reach a broader audience of nearly 4.5m investors and opinion-formers via columns in the following influential newspapers: The New York Times (USA), The Telegraph (UK), The International Herald Tribune, Le Monde (France), El Pais and Cinco Dias (Spain), Handelsblatt (Germany), La Stampa (Italy), NRC Handelsblad (Netherlands), The National (UAE), The Business Times (Singapore), Mint (India) and L’Agefi (Switzerland).

The largest US pension fund is bothered by the fees it has paid Apollo. It has already endorsed calls for lower fees and giving investors in private equity more say. If Calpers does put the screws on Apollo, other big investors - and other buyout firms - won't be far behind.

Sign up for a free trial to read the rest of this subscriber-only content, or if you are already a member please sign in here.

Forgotten your password? Get a password reminder.


More stories by:  Lauren Silva Laughlin






Share